ANI Pharmaceuticals Inc (NASDAQ:ANIP) has earned a consensus rating of “Buy” from the seven analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $73.25.
A number of brokerages recently issued reports on ANIP. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $76.00 price objective on the stock in a report on Thursday. Raymond James set a $73.00 price objective on ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, February 28th. TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 19th. BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, February 14th. Finally, ValuEngine raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 4th.
Shares of ANIP stock traded up $2.78 on Tuesday, hitting $70.54. 230,232 shares of the stock were exchanged, compared to its average volume of 81,295. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.68 and a current ratio of 0.92. The company has a market capitalization of $835.97 million, a price-to-earnings ratio of 15.30 and a beta of 2.41. ANI Pharmaceuticals has a one year low of $36.92 and a one year high of $72.81.
In other ANI Pharmaceuticals news, SVP Robert W. Schrepfer sold 4,651 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $64.43, for a total value of $299,663.93. Following the sale, the senior vice president now owns 53,484 shares of the company’s stock, valued at approximately $3,445,974.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Arthur Przybyl sold 27,625 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $63.53, for a total value of $1,755,016.25. The disclosure for this sale can be found here. Corporate insiders own 33.10% of the company’s stock.
Several large investors have recently added to or reduced their stakes in ANIP. First Trust Advisors LP purchased a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at about $710,000. Teachers Retirement System of The State of Kentucky raised its holdings in shares of ANI Pharmaceuticals by 99.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 2,005 shares of the specialty pharmaceutical company’s stock valued at $113,000 after acquiring an additional 1,000 shares in the last quarter. Panagora Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals during the 3rd quarter valued at about $1,052,000. Dimensional Fund Advisors LP raised its holdings in shares of ANI Pharmaceuticals by 6.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 511,881 shares of the specialty pharmaceutical company’s stock valued at $28,941,000 after buying an additional 32,556 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of ANI Pharmaceuticals by 2.9% during the 3rd quarter. Renaissance Technologies LLC now owns 178,400 shares of the specialty pharmaceutical company’s stock valued at $10,087,000 after buying an additional 5,100 shares in the last quarter. 59.75% of the stock is currently owned by hedge funds and other institutional investors.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
Featured Story: Stop Order Uses For Individual Investors
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.